FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2271278148> ?p ?o ?g. }

• W2271278148 endingPage "31" @default.
• W2271278148 startingPage "27" @default.
• W2271278148 abstract "Involvement of the skeleton can cause an excruciating pain in two-thirds of terminal patients with a history of malignancy. Due to several limitations of other therapies, such as analgesics, bisphosphonates, chemotherapy, hormonal therapy and external beam radiotherapy; bone-seeking radiopharmaceuticals have an important role in palliation of pain from bone metastases. Although these kinds of therapies have many advantages including the ability to treat multiple sites of tumoral involvement simultaneously, no significant confliction with other treatments, ease of administration and the potential to be used repetitively; in Iran using of this modality is not widely practiced. In this study we evaluated the clinical usefulness of Sm-153 lexidronamfor pain management of bone metastases.28 patients (14 males and 14 females) aged 38-77 years with a history of painful bone metastases caused by different cancers, not responding to conventional treatments were included in the study. All patients had a recent whole body bone scan indicating multiple bone metastases. 1 mCi/Kg Sm-153 lexidronam was injected intravenously to the patients. Whole body scintigraphy was done 3 or 18 hours post injection. Pain relief and quality of life have been evaluated by analog pain scale and Karnofsky index every week, respectively. Also, all patients were evaluated for hematological toxicity every two weeks. Active follow ups were performed.43% of patients showed the presence of the flare phenomenon during the first three days after Sm injection with a mean duration of 2.2 days. The pain relief began between 2 and 16 days post injection and the duration of pain palliation was in the range of 4 to 32 weeks (mean±SD=15.22±7.8). 64.3% of patients showed complete relief of pain and 21.4% achieved partial response to therapy. (Over all response to therapy was 85.7%). The lowest amount of peripheral blood cells was detected in the fourth week for RBCs and in the 6th week for WBCs and PLTs. No one experienced hematological toxicity induced problems.Sm-153 lexidronam is an effective treatment for painful bone metastases. The complication rate is low and the quality of life of the patients after treatment would be significantly improved." @default.
• W2271278148 created "2016-06-24" @default.
• W2271278148 creator A5003971714 @default.
• W2271278148 creator A5010691273 @default.
• W2271278148 creator A5044242006 @default.
• W2271278148 creator A5045430810 @default.
• W2271278148 creator A5061405691 @default.
• W2271278148 creator A5062437542 @default.
• W2271278148 creator A5084894008 @default.
• W2271278148 creator A5089794273 @default.
• W2271278148 date "2013-01-01" @default.
• W2271278148 modified "2023-10-16" @default.
• W2271278148 title "Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis." @default.
• W2271278148 cites W1569395967 @default.
• W2271278148 cites W1964390282 @default.
• W2271278148 cites W1993798152 @default.
• W2271278148 cites W1998848708 @default.
• W2271278148 cites W2007745674 @default.
• W2271278148 cites W2009671106 @default.
• W2271278148 cites W2010849237 @default.
• W2271278148 cites W2014746711 @default.
• W2271278148 cites W2030224343 @default.
• W2271278148 cites W2033443281 @default.
• W2271278148 cites W2089775577 @default.
• W2271278148 cites W2102995554 @default.
• W2271278148 cites W2108516276 @default.
• W2271278148 cites W2114808940 @default.
• W2271278148 cites W2118355978 @default.
• W2271278148 cites W2408620695 @default.
• W2271278148 cites W2412811040 @default.
• W2271278148 cites W2418383879 @default.
• W2271278148 doi "https://doi.org/10.7508/aojnmb.2013.01.006" @default.
• W2271278148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4937668" @default.
• W2271278148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27408839" @default.
• W2271278148 hasPublicationYear "2013" @default.
• W2271278148 type Work @default.
• W2271278148 sameAs 2271278148 @default.
• W2271278148 citedByCount "10" @default.
• W2271278148 countsByYear W22712781482015 @default.
• W2271278148 countsByYear W22712781482016 @default.
• W2271278148 countsByYear W22712781482017 @default.
• W2271278148 countsByYear W22712781482020 @default.
• W2271278148 countsByYear W22712781482021 @default.
• W2271278148 countsByYear W22712781482022 @default.
• W2271278148 crossrefType "journal-article" @default.
• W2271278148 hasAuthorship W2271278148A5003971714 @default.
• W2271278148 hasAuthorship W2271278148A5010691273 @default.
• W2271278148 hasAuthorship W2271278148A5044242006 @default.
• W2271278148 hasAuthorship W2271278148A5045430810 @default.
• W2271278148 hasAuthorship W2271278148A5061405691 @default.
• W2271278148 hasAuthorship W2271278148A5062437542 @default.
• W2271278148 hasAuthorship W2271278148A5084894008 @default.
• W2271278148 hasAuthorship W2271278148A5089794273 @default.
• W2271278148 hasConcept C121608353 @default.
• W2271278148 hasConcept C126322002 @default.
• W2271278148 hasConcept C126838900 @default.
• W2271278148 hasConcept C141071460 @default.
• W2271278148 hasConcept C159110408 @default.
• W2271278148 hasConcept C2776049877 @default.
• W2271278148 hasConcept C2776139714 @default.
• W2271278148 hasConcept C2776694085 @default.
• W2271278148 hasConcept C2777783956 @default.
• W2271278148 hasConcept C2779013556 @default.
• W2271278148 hasConcept C2779399171 @default.
• W2271278148 hasConcept C2779951463 @default.
• W2271278148 hasConcept C2989005 @default.
• W2271278148 hasConcept C2993559085 @default.
• W2271278148 hasConcept C509974204 @default.
• W2271278148 hasConcept C71924100 @default.
• W2271278148 hasConceptScore W2271278148C121608353 @default.
• W2271278148 hasConceptScore W2271278148C126322002 @default.
• W2271278148 hasConceptScore W2271278148C126838900 @default.
• W2271278148 hasConceptScore W2271278148C141071460 @default.
• W2271278148 hasConceptScore W2271278148C159110408 @default.
• W2271278148 hasConceptScore W2271278148C2776049877 @default.
• W2271278148 hasConceptScore W2271278148C2776139714 @default.
• W2271278148 hasConceptScore W2271278148C2776694085 @default.
• W2271278148 hasConceptScore W2271278148C2777783956 @default.
• W2271278148 hasConceptScore W2271278148C2779013556 @default.
• W2271278148 hasConceptScore W2271278148C2779399171 @default.
• W2271278148 hasConceptScore W2271278148C2779951463 @default.
• W2271278148 hasConceptScore W2271278148C2989005 @default.
• W2271278148 hasConceptScore W2271278148C2993559085 @default.
• W2271278148 hasConceptScore W2271278148C509974204 @default.
• W2271278148 hasConceptScore W2271278148C71924100 @default.
• W2271278148 hasIssue "1" @default.
• W2271278148 hasLocation W22712781481 @default.
• W2271278148 hasOpenAccess W2271278148 @default.
• W2271278148 hasPrimaryLocation W22712781481 @default.
• W2271278148 hasRelatedWork W153610466 @default.
• W2271278148 hasRelatedWork W2152467020 @default.
• W2271278148 hasRelatedWork W2159850384 @default.
• W2271278148 hasRelatedWork W2353290694 @default.
• W2271278148 hasRelatedWork W2356639633 @default.
• W2271278148 hasRelatedWork W2357763740 @default.
• W2271278148 hasRelatedWork W2389319713 @default.
• W2271278148 hasRelatedWork W2393653253 @default.
• W2271278148 hasRelatedWork W3031376164 @default.

• next